Galapagos beefs up its fibrosis pipeline, lassoing 4 more programs and taking a stake in small Canadian partner
With big money pacts with Gilead and AbbVie under its belt, Galapagos has become a hefty partner to smaller biotech players in its own right.
The Belgian biotech has expanded a collaboration with Fibrocor Therapeutics — grabbing exclusive options to four more fibrosis programs and taking an equity stake in the company. Once Fibrocor completes the research work up to lead optimization, Galapagos may take over development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.